DOI: 10.1097/QAD.0b013e328354c9dc
,
,
PMID: 22767345
Issn Print: 0269-9370
Publication Date: 2012/07/17
Beneficial course of two cases of HIV-associated multicentric Castleman disease treated with HIV antiretroviral therapy
Christiane Rosin; Flurina Hostettler; Luigia Elzi; Stephan Dirnhofer; Manuel Battegay
+ Author Information
Author Information: Division of Infectious Diseases and Hospital Epidemiology
Excerpt
Multicentric Castleman disease (MCD) is a lymphoproliferative opportunistic tumor occurring in HIV-patients strongly associated with the human herpesvirus (HHV)-8 and with high mortality rates [1]. Therapeutic options include lymphoma-type chemotherapy, virostatics and/or immunomodulators [2]. So far, no standard treatment exists because no randomized controlled trials can be performed due to the rarity of the disease [3]. Chemotherapy may further limit immune recovery and control of HHV-8, and thereby hamper remission of MCD.
Facebook
Twitter
LinkedIn
Email
